1Firpi R J, Clark V, Seldevila-Pico C, et al. Teh natural history of hepatitisC cirrhosis afterliver transplantion[J]. Liver Transpl, 2009, 15 ( 9 ) : 1063-1071.
1[1]BOOTH JCL, O'GRADY J, NEUBERGER J. Clinical guidelines on the management of hepatitis C[J]. Gut,2001,49 Suppl I:i1-i21.
2[2]Anon. EASL international consensus conference on hepatitis C[J]. J Hepatol,1999,31 Suppl 1:3-8.
3[3]Anon. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention[J]. MMWR Recomm Rep,1998,47(RR-19):1-39.
4[4]LAUER GM, WALKER BD. Hepatitis C virus infection[J]. N Engl J Med,2001,345(1):41-52.
5[5]DAVIS GL, ESTEBAN-MUR R, RUSTGI V, et al. Interfection alfa-2b alone or in combination with ribavirin for the treatment of repapse of chronic hepatitis C[J]. N Engl J Med,1998,339(21):1493-1499.
6[6]NEUMANN AU, LAM NP, DAHARI H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy[J]. Science,1998,282(5386):103-107.
7[7]PEPINSKY RB, LEPAGE DJ, GILL A, et al. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity[J]. J Pharmacol Exp Ther,2001,297(3):1059-1066.
8[8]GLUE P, FANG JW, ROUZIER-PANIS R, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data[J]. Clin Pharmacol Ther,2000,68(5):556-567.
9[9]LINDSAY KL, TREPO C, HEINTGES T, et al. A randomized, double-blind trial comparing pegylated inteferon alfa-2b to inteferon alfa-2b as initial treatment for chronic hepatitis C[J]. Hepatology,2001,34(2):395-403.
10[10]ZEUZEM S, FEINMAN SV, RASENACK J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C[J]. N Engl J Med,2000,343(23):1666-1672.
